Ecromeximab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458638350

| type = mab

| mab_type = mab

| source = xi/o

| target = GD3 ganglioside

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 292819-64-8

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = M76FX2JZRM

| chemical_formula =

| molecular_weight = 145255

| molecular_weight_comment = g/mol

}}

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.{{cite web | title = Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab | url = https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/ecromeximab.pdf | publisher = American Medical Association }}{{ClinicalTrialsGov|NCT00679289|Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma}}{{cite journal | vauthors = Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM | title = Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma | journal = Melanoma Research | volume = 27 | issue = 4 | pages = 342–350 | date = August 2017 | pmid = 28489678 | doi = 10.1097/CMR.0000000000000353 }}

The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.{{cite web | title = Ecromeximab | url = http://adisinsight.springer.com/drugs/800013219 | work = AdisInsight }}